Shantha Biotechnics Consents to Manufacture Dengue Vaccine
InViragen’s lead product to be produced for preclinical studies and clinical trials.
Shantha Biotechnics will manufacture InViragen’s dengue vaccine candidate under an agreement between the two companies. This vaccine will be used to complete preclinical studies and initiate testing of its safety and efficacy in humans.
The vaccine was designed by collaborators at the CDC to protect against all four of the dengue viruses. "InViragen and the CDC are using innovative recombinant technologies to create a novel vaccine," says Varaprasad Reddy, M.D., managing director of Shantha Biotechnics.